: Fresh data from the Heart Rhythm 2026 conference continues to support the safety and efficacy of key franchises like FARAPULSE and WATCHMAN . The Sell Case: Rising Risks

: The company reported Q1 2026 revenue of $5.20B and adjusted EPS of $0.80, both slightly beating market expectations.

Data at Heart Rhythm 2026 highlight key Boston Scientific therapies

Bsx Stock Buy Or Sell -

: Fresh data from the Heart Rhythm 2026 conference continues to support the safety and efficacy of key franchises like FARAPULSE and WATCHMAN . The Sell Case: Rising Risks

: The company reported Q1 2026 revenue of $5.20B and adjusted EPS of $0.80, both slightly beating market expectations.

Data at Heart Rhythm 2026 highlight key Boston Scientific therapies